ArticleBreast cancer research and treatment2014

Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.

Thomas Bachelot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.